Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
Spyre Therapeutics announced that SPY002, its anti-TL1A investigational antibody for moderate-to-severe ulcerative colitis (UC), met its primary endpoint in the Phase 2 SKYLINE trial Part A. The therapy demonstrated a significant reduction in Robart's Histopathology Index score by 10.7 points at Week 12, with notable clinical remission and endoscop…